Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AngioScore

AngioScore
2003 FOUNDED
M&A STATUS
101-200 EMPLOYEES
M&A LATEST DEAL TYPE
$230M LATEST DEAL AMOUNT
Description

Developer of tools for endovascular therapy. The company develops angioplasty catheters for use in the treatment of cardiovascular and vascular disease.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Parent Company
Primary Office
  • 5055 Brandin Court
  • Fremont, CA 94538
  • United States

+1 (510) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AngioScore’s full profile, request a free trial.

AngioScore Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 30-Jun-2014 $230M 000.00 00000 Completed Generating Revenue
8. Secondary Transaction - Private 24-Jul-2012 00000 000.00 Completed Generating Revenue
7. Secondary Transaction - Private 000.00 Completed
6. Later Stage VC (Series F) 20-Apr-2011 0000 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series E) 09-Oct-2007 0000 000.00 00000 Completed Generating Revenue
4. Later Stage VC (Series D) 11-Apr-2006 000.00 000.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 19-Jul-2005 00.000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Aug-2004 $15.1M $16.8M 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 28-Mar-2003 $1.63M $1.63M 00.000 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

AngioScore Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series F 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series D 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 6,751,590 $0.001000 8% $2.24 $2.24 1x $2.17 15.17%
Series A1 1,632,434 $0.001000 8% $1 $1 1x $1 3.55%
To view this company’s complete Cap Table, request access »

AngioScore Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mercator MedSystems Venture Capital-Backed Emeryville, CA 00 000.00 00000000000 000.00
0000 000 Formerly PE-Backed Vaulx-en-Velin, France 000 0000 00000000 0000
000000000 0000000 Formerly VC-backed Santa Clara, CA 000 00000 00000000 00000
0000000 Formerly VC-backed Mountain View, CA 00 000.00 000000&0 000.00
000000000 Venture Capital-Backed Tirat Carmel, Israel 000 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

AngioScore Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
California Technology Ventures Venture Capital Minority 000 0000 000000 0
Industry Ventures Venture Capital Minority 000 0000 000000 0
Innomed Ventures Venture Capital Minority 000 0000 000000 0
Jerusalem Global Ventures Venture Capital Minority 000 0000 000000 0
Linkagene Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

AngioScore Executive Team (11)

Name Title Board
Seat
Contact
Info
Thomas Trotter President & Chief Executive Officer
Victor Hwang Managing Director
Gary Gershony MD Chief Medical Officer & Founder
Stephen Zielinski Senior Sales Director
Kent Jones Senior Vice President, Regulatory and Quality

2 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

AngioScore Board Members (12)

Name Representing Role Since Contact
Info
James Armstrong Self Board Member 000 0000
Robert Elliott Self Board Member 000 0000

10 Former Board Members

You’re viewing 2 of 12 board members. Get the full list »